Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by ...

Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for demyelinating ...

Remains on track to name a development candidate for a novel first-in-class neurology program targeting demyelinating diseases in 2026Progresses discovery work on a best-in-class cell therapeutic ...

Neuromyelitis optica spectrum disorder (NMOSD) and related demyelinating diseases, including myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), represent a spectrum of autoimmune ...

Demyelinating disease, including multiple sclerosis and neuromyelitis optica, can affect children and teens. Our program works closely with the Multiple Sclerosis Program at University of Utah ...

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults ...

A new report examined optic nerve lesion length, measured on brain magnetic resonance imaging, at the acute phase of ON in 51 individuals. Optic nerve lesion length was significantly associated with ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

THE demyelinating diseases of the nervous system remain a challenge to scientific investigation and a stumbling block in medical therapy. Comprising an important group of neurologic disorders, they ...

NMOSD accounts for 1 to 2% of all cases of CNS inflammatory demyelinating disease in the United States and Europe, with multiple sclerosis being much more common, but NMOSD accounts for one third or ...